Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

My previous session
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

L'Oreal ready to buy Nestle stake in cosmetics leader

share with twitter share with LinkedIn share with facebook
share via e-mail
02/09/2018 | 03:41pm CEST
FILE PHOTO: Bottles of shampoos, conditioners and color spray are displayed at cosmetics company L'Oreal's new World hair research centre in Saint-Ouen near Paris

PARIS (Reuters) - L'Oreal (>> L'Oréal) on Friday underscored its readiness to buy Nestle's (>> Nestlé) 23 percent stake in the world's biggest cosmetics firm were its Swiss shareholder to sell, saying it had access to cash and funding at its disposal.

PARIS (Reuters) - L'Oreal (>> L'Oréal) on Friday underscored its readiness to buy Nestle's (>> Nestlé) 23 percent stake in the world's biggest cosmetics firm were its Swiss shareholder to sell, saying it had access to cash and funding at its disposal.

L'Oreal said it could finance a purchase of the holding, now worth around 22.3 billion euros (19.64 billion pounds), with cash, by selling its stake in French drugmaker group Sanofi (>> Sanofi) or through borrowing if needed.

"If Nestle one day wants to sell, we are ready," Chairman and Chief Executive Jean-Paul Agon told a news conference, after L'Oreal released slightly better-than-expected fourth-quarter earnings.

The death of L'Oreal heiress Liliane Bettencourt last September set the clock ticking on the end of 44-year-old shareholder pact between the French company's founding family and Nestle.

The agreement prevented the Bettencourts, which have 33 percent of L'Oreal, and the Swiss food group from raising their holdings. It is now set to expire in mid-March, stirring speculation over the shareholders' relationship and whether Nestle might sell out or even contemplate a takeover.

Nestle had previously been at liberty to whittle down its L'Oreal holding, however, and has yet to budge, in spite of pressure from activist investor Daniel Loeb, founder of hedge fund Third Point. Loeb has pushed for a sale among demands for the Swiss firm to speed up a strategy overhaul.

"We have 1.8 billion euros in cash, we have the Sanofi stake. We are also a very serious and loyal and active shareholder in Sanofi, but in case we will be ready and I'm sure if it was not enough, we have many love letters from banks that have said that they would love to lend us some money," Agon said.

Nestle and Sanofi declined to comment. Shares in L'Oreal, maker of Garnier shampoo and cosmetics labels like Lancome, were up 1.3 percent at 1413 GMT, among the top gainers on France's blue-chip CAC-40 <.FCHI> index. Nestle shares were up 0.6 percent, while Sanofi was 0.9 percent lower.


Nestle has so far given no signs it could sell out of L'Oreal.

"Our approach to this investment is currently not changing," Nestle CEO Mark Schneider told investors in September.

The L'Oreal stake is worth about 10 percent of Nestle's market capitalisation and has contributed to its earnings, but some investors, including Loeb, think that money could be put to better use.

Loeb has praised Nestle's chief for other recent steps such as buying back stock, buying and selling some assets and bringing new directors onto the board.

Others say that Nestle should keep the stake until it has something else in mind to buy.

Nestle was interested in the vitamin and supplements business being sold by Merck (>> Merck KGaA), but has dropped out of the running.

L'Oreal already bought an 8 percent stake in the firm from Nestle in 2014, and cancelled the shares. That 6.5 billion-euro deal allowed both companies to boost their earnings per share.

Buying the remaining 23 percent could be positive for L'Oreal, some analysts said.

"This may excite some: an acquisition of the stake by L'Oreal, part-funded by a sale of its own Sanofi stake would be circa 10 percent accretive," Investec Securities analysts said in a note.

At today's stock price, L'Oreal's 9 percent stake in Sanofi - a legacy from its incursion into the pharmaceuticals business in 1973, before the modern day Sanofi was formed - is worth more than 7 billion euros, according to Reuters data.

L'Oreal's Agon said on Thursday he was confident of significant growth in like-for-like sales in 2018. The company, whose brand ambassadors include Helen Mirren, Eva Longoria and Blake Lively, was boosted last year by strong sales in Asia and demand for its luxury products.

(Reporting by Dominique Vidalon, Sarah White, Martinne Geller, Matthias Blamont and Pascale Denis; Editing by Alexander Smith and David Evans)

By Sarah White and Dominique Vidalon

Stocks treated in this article : L'Oréal, Sanofi, Merck KGaA, Nestlé
Stocks mentioned in the article
ChangeLast1st jan.
L'ORÉAL 0.82% 208.2 Real-time Quote.11.65%
MERCK KGAA 0.74% 89.76 Delayed Quote.-0.72%
NESTLÉ 0.40% 80.96 Delayed Quote.-3.77%
SANOFI -0.87% 72.85 Real-time Quote.2.28%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
03:34pCatalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmac..
08/10MERCK : Germany's Merck Boosts Hedges Against Currency Gyrations
08/09AFTER MORE THAN FOUR DECADES AT MERC : Walter Galinat to Retire
08/09MERCK : 2Q Sales Edged Up; 2018 Outlook Confirmed
08/09PROCTER & GAMBLE : Merck KGaA profit dragged lower by liquid crystal decline, fo..
08/09MERCK : Darmstadt, Germany, Reports Solid Organic Performance in Q2 2018
08/09MERCK KGAA : Half-year results
08/09MERCK KGAA : Slide show half-year results
08/07MERCK : Mercks 10k synthesis competition will lab test routes
08/06MERCK KGAA : half-yearly earnings release
More news
News from SeekingAlpha
08/13Merck KGaA (MKGAF) CEO Stefan Oschmann on Q2 2018 Results - Earnings Call Tra.. 
08/09Merck KGaA 2018 Q2 - Results - Earnings Call Slides 
08/09Ziopharm up 24% after Q2 report 
08/09Merck KGaA reports Q2 results 
08/023 THINGS IN BIOTECH, AUGUST 2 : Japanese Drug Makers Rise And Fall 
Financials (€)
Sales 2018 14 510 M
EBIT 2018 2 851 M
Net income 2018 2 065 M
Debt 2018 7 300 M
Yield 2018 1,40%
P/E ratio 2018 18,04
P/E ratio 2019 20,51
EV / Sales 2018 1,30x
EV / Sales 2019 1,11x
Capitalization 11 627 M
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 98,0 €
Spread / Average Target 10,0%
EPS Revisions
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-0.72%13 252
ABBVIE-0.94%152 023